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Objective This study was aimed at the development of a DNA-based procedure directly
applicable to pathological skin scales and at the assessment of its value in rapid
laboratory confirmation and identification of each of the seven Malassezia species. These
lipophilic basidiomycetous yeasts in predisposed individuals are involved in pityriasis
versicolor, seborrheic dermatitis, blepharitis, folliculitis, atopic dermatitis and fungemia.
Standard identification procedures to species level are available, but so far no system for
direct detection and characterization of Malassezia species in clinical specimens is
available.
Methods Malassezia DNA was extracted from pathological skin scales by a modified
hexadecyltrimethylammonium bromide (CTAB) method and amplified by single and
nested polymerase chain reaction (PCR), assays using the general fungal ITS 1/4 and 3/4
primers for amplification of sequences from the Malassezia major ribosomal DNA
complex. Restriction fragment length polymorphism (RFLP) analysis of PCR products
was used in subsequent species identification. DNA extracted from culture-positive skin
scales was also tested by PCR and the RFLP patterns obtained were analyzed.
Results A total of 36 isolates were tested. Distinct pure culture and skin-scale ITS 3/4
HinfI and AluI restriction patterns differentially identified M. furfur, M. globosa, M.
restricta, M. sympodialis, M. pachydermatis, M. obtusa and M. slooffiae. Malassezia DNA
was extracted from pathological skin scales and RFLP identified solitary and multiple
Malassezia species in the same specimen. Molecular identification was confirmed by
cultures and biochemical tests. Concurrent detection and identification of Candida and
Yarrowia species was also feasible from skin scales.
Conclusion The proposed method, described for the first time, could provide a sensitive
and rapid detection and identification system for Malassezia species, which may be
applied to epidemiological surveys and routine practice.
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I N T R O D U C T I O N
For many years the nomenclature and taxono-
mic status of the genus Malassezia has been
controversial. This was recently resolved and four
new species (M. globosa, M. obtusa, M. slooffiae and
M. restricta) were incorporated into the genus,
which originally included only three species (M.
furfur, M. pachydermatis and M. sympodialis) [1].
Yeasts of the genus Malassezia inhabit healthy
and diseased skin in sites rich in sebaceous glands
such as the thorax, the interscapular region and the
forehead. Apart from causing pityriasis versicolor
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Corresponding author and reprint requests: A. Velegraki,
Vrastovou 2–4, Ampelokipi, Athens 115 24, Greece
Tel: þ301 7462146
Fax: þ301 7462147
E-mail: avelegr@cc.uoa.gr
Malassezia species have been implicated in sebor-
rheic dermatitis and blepharitis, folliculitis, dan-
druff and atopic dermatitis [2] although the
pathogenetic relationship is obscure. It has also
been reported that the non-lipid-dependent M.
pachydermatis is implicated in epidemics of folli-
culitis in intensive care unit patients, possibly
acquired from fomites [3,4].
As two of the new Malassezia species, M. obtusa
and M. restricta, are difficult to grow, the isolation
rate of individual species in culture may not be
representative of the actual flora, casting doubt on
possible species-specific pathology. Due to the
lipid dependence of the organism, sugar fermen-
tation tests are not appropriate for species differ-
entiation. At present, all species are identified
according to colony morphology, microscopic
characteristics and by time-consuming and com-
plicated lipid assimilation tests [5,6]. Identification
by these conventional tests can be confirmed by
elaborate and costly methods of no direct diag-
nostic significance, such as pulsed field gel elec-
trophoresis (PFGE), recombinant RNA sequencing
and nuclear DNA comparisons [7,8]. Conversely,
the less costly and more rapid PCR-based method
of random amplification of polymorphic DNA
(RAPD) has been frequently used to investigate
epidemics, as in a neonatal intensive care unit [3].
In light of the intricacy of interpreting the bio-
chemical tests required for characterizing each
species of human and veterinary origin [9], a direct
and economical method for the detection and
identification of the Malassezia species would be
a useful diagnostic tool in veterinary mycology
and in epidemiological surveys. However, detec-
tion and identification of Malassezia species DNA
by direct tests on skin scales from pathological
specimens has not yet been reported.
The aim of this study was two-fold. Firstly, we
planned to build up a ‘library’ of restriction endo-
nuclease patterns of Malassezia species amplifica-
tion products generated by the internal transcribed
spacer (ITS) 3/4 primers – which amplify the 5.8S
and part of the 28S region of the major nuclear ribo-
somal DNA complex. Secondly, we intended to use
the restriction ‘library’ data in the development of
a rapid PCR-based method for testing small quan-
tities of patient skin scalessoas to detect directly and
confirm the identity of Malassezia species.
M A T E R I A L S A N D M E T H O D S
Strains and patients
A total of 36 strains consisted of five Type strains
(M. sympodialis CBS 7222; M. slooffiae CBS 7956; M.
globosa CBS 7966; M. obtusa CBS 7876; M. restricta
CBS 7877), two Neotype strains (M. furfur CBS
7019; M. pachydermatis CBS 1879), two Reference
strains (M. furfur CBS 6001; M. furfur Institute
Pasteur – IP 1363-82) and 20 clinical strains isolated
from lesions of scalp, neck and trunk [M. furfur
(three strains), M. sympodialis (four strains), M.
slooffiae (two strains), M. restricta (three strains),
M. pachydermatis, isolated from ear lesions of a
dog (one strain) and M. globosa (seven strains)]
(Table 1). In addition, more clinical isolates were
Table 1 Dermatological condition and isolation of Malassezia clinical strains from different anatomical sites
Malassezia species Skin disease Sampled region
1. M. furfur and M. globosa Pityriasis versicolor Interscapular region
2. M. furfur Pityriasis versicolor Sternum
3. M. furfur Pityriasis versicolor Back
4. M. sympodialis Pityriasis versicolor Interscapular region
5. M. sympodialis and M. globosa Pityriasis versicolor Back
6. M. sympodialis Pityriasis versicolor Chest
7. M. sympodialis Pityriasis versicolor Neck
8. M. restricta and M. globosa Pityriasis versicolor Back
9. M. restricta Seborrheic dermatitis Head
10. M. restricta Seborrheic dermatitis Head
11. M. slooffiae Seborrheic dermatitis Head
12. M. slooffiae Seborrheic dermatitis Mid-eyebrow region
13. M. globosa Seborrheic dermatitis Pre-auricular region
14. M. globosa Pityriasis versicolor Neck
15. M. globosa Pityriasis versicolor Sternum
16. M. globosa Pityriasis versicolor Interscapular region
17. M. pachydermatis Dog otitis External ear
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included, comprising strains of M. sympodialis
(two strains), M. globosa (two strains), M. obtusa
(two strains) and M. pachydermatis (one strain),
donated by Gillian Midgley (St. John’s Institute
of Dermatology, St. Thomas Hospital, London,
UK).
The Hospital Ethics Committee approved the
protocol, and the skin-scale samples were taken
following informed patient consent.
Identification procedures
Conventional identification to species level
was achieved as previously described [5,6].
Briefly, M. restricta was identified by the nega-
tive catalase test. In order to exclude the remote
possibility of the presence of a rare M. pachyder-
matis in human skin, isolates were also tested
for their ability to grow, in subsequent subcul-
tures, on a lipid-free medium. The other species
were identified according to their microscopic
characteristics and their ability to assimilate
Tween-20, -40 and -80 and Cremophor El [6]
(Sigma, MO, USA). Esculin hydrolysis tests
were also employed to confirm the identity of
M. sympodialis.
Other yeasts, such as Candida and Yarrowia spe-
cies, which were simultaneously isolated with
Malassezia species in cultures of skin scales, were
identified according to their carbohydrate assimila-
tion profile by the API ID 32C system (BioMe´rieux,
Marcy l0 Etoil, France), followed by confirma-
tory additional physiological and morphological
tests.
Antifungal susceptibility testing
Only Yarrowia (Candida) lipolytica susceptibility
tests were performed, because to our knowledge
this is its first report as a Malassezia co-isolate from
human lesions. The minimum inhibitory concen-
trations (MIC) of amphotericin B, 5-flucytosine,
itraconazole, fluconazole, ketoconazole and vori-
conazole were determined against three Y. lipoly-
tica strains , one each from seborrheic dermatitis of
the scalp, face and trunk, and two from candide-
mia cases, by the NCCLS microdilution reference
method for yeasts [10] with C. krusei ATCC 6258
and C. parapsilosis ATCC 22019 used as Quality
Control strains and C. albicans ATCC 90028 as a
Reference strain. The MIC100 was optically read for
amphotericin B, and MIC80 was read for all other
antifungals after 48 h incubation at 28–30 8C in five
independent single colony-forming unit (CFU)
assays, and the range of MIC values for Y. lipolytica
was recorded.
DNA extraction from pure cultures
All reference strains and clinical isolates were
grown and maintained on modified Dixon’s agar
(3.6% malt extract agar, 0.6% mycological peptone,
1% agar No. 1, 2% ox bile, 1% Tween-40, 0.2%
glycerol (all from Oxoid, Basingstoke, UK) and
0.2% oleic acid), at 32 8C for 8 days. The require-
ment for lipid-containing media resulted in either
frequent failure to extract DNA from pure culture,
or a very poor DNA yield. Therefore, to achieve
adequate yeast cell lysis and sufficient DNA purity
for PCR amplification, a modification of the
method proposed by the manufacturers of the
Silica extraction kit (MBI, Fermentas, Lithuania)
was incorporated into the extraction protocol as
follows. A standard loopful of volume capacity
103 (Greiner GmbH, Germany) of yeast pure
culture was suspended in 100 ml lysis buffer
[(200 mM Tris–HCl, pH 8, 250 mM NaCl, 25 mM
ethylenediamine-tetraacetic acid (EDTA), 0.5%
sodium dodecyl sulfate (SDS) (all from Sigma)]
as previously described [11]. Cells were disrup-
ted mechanically with an orbital homogenizer,
following addition of a further 350 ml lysis buffer.
DNA was extracted once by suspending the
homogenate in an equal volume of phenol : chlor-
oform : isoamyl alcohol (vol : vol : vol, 25 : 24 : 1).
After 60 min centrifugation at 4 8C and 13 680 g,
the upper aqueous layer was transferred into a
new microcentrifuge tube, mixed with an equal
volume of molecular grade phenol (Sigma) and
centrifuged at room temperature at 22 570 g for
10 min. The extraction method suggested by
the manufacturer was then applied to the super-
natant.
Sensitivity of the CTAB extraction method
Sensitivity was determined using pure cultures as
described previously [11,12].
DNA extraction from scalp, neck and trunk
skin scales
Skin scales from 11 patients (three with scalp
and interscapular seborrheic dermatitis and
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eight with trunk pityriasis versicolor) were col-
lected and transferred to the laboratory sealed
between two microscope slides. A portion of the
pathological material was microscopically exam-
ined, and following confirmation of the presence
of the yeast cells, a quantity of the remaining
skin scales was inoculated on Dixon’s agar,
while a loopful of the remaining scales where
collected with a disposable standard 103 in-
oculation loop (greiner), moistened in sterile
phosphate-buffered saline to facilitate adherence
of the skin scale, and processed for DNA
extraction.
No skin scales from healthy individuals were
used, as at this stage the aim of the study was to
evaluate the potential of the extraction/identifica-
tion method from pathological skin scales and not
from sebum, as would have been the case if
healthy individuals with no scaly lesions had been
tested.
Malassezia DNA was extracted using a modifi-
cation of the CTAB method as previously
described [12]. This strong cationic detergent
was selected as a DNA carrier because it has been
traditionally very effectively used in lysing robust
chitinized tissues and it is highly sensitive in
nucleic acid isolation from small samples [12], as
in the case of attempting to extract DNA from a
small amount of skin scales. Briefly, the skin
scales were suspended in 100 ml buffer [5% CTAB
(Sigma); 700 mM Tris–HCl, pH 8; 10 mM EDTA;
and 5% 2-mercaptoethanol]. Skin scales and
yeast cells were mechanically disrupted for
3 min in an orbital homogenizer. To the hom-
ogenate, 400 ml of CTAB buffer was added and
following incubation for 30 min at 65 8C with occa-
sional swirling, chloroform : isoamyl alcohol (vol :
vol, 24 : 1) extraction was performed. Following
centrifugation at 8000 g for 10 min at room tem-
perature the aqueous phase was obtained and
nucleic acids were precipitated with an equal
volume of cold isopropanol by centrifugation at
room temperature and 8000 g for 10 min. The pellet
was washed in 500 ml wash buffer (76% ethanol,
10 mM ammonium acetate) by standing at room
temperature, for 15 min. DNA was precipitated
after centrifugation at room temperature and
8000 g for 10 min. The wash buffer was removed
carefully, so as not to loosen the pellet, which
was allowed to dry briefly for 2–4 min before
washing the DNA in 70% ethanol to collect the
nucleic acids by centrifugation as before. The
pellet was dried and resuspended in 30–40 ml
sterile double-distilled water.
Primers and hot-start PCR reaction conditions
The general fungal ITS 1 (50-TCCGTAGGTGAAC
CTGCGG-30), ITS 3 (50-GCATCGATGAAGAACG
CAGC-30), and ITS 4 (50-TCCTCCGCTTATTGAT
ATGC-30) primers (Interactiva, GmbH, Germany),
as defined by White et al. [13], were used to
amplify Malassezia species sequences. Each ampli-
fied sequence contains flanking parts of two of the
three rRNA genes (18S, 5.8S and 28S and either or
both of the ITS 1 and 2 regions (which flank the
5.8S rRNA gene) and hold enough variation to
define given species. The target DNA was
extracted from pure cultures and from patient skin
scales obtained from lesions. The 50 ml of the PCR
master mix contained 6 ml MgCl2 (25 mM), 10 ml
Mg2þ-free buffer (100 mM Tris–HCl, 500 mM KCl
and 1% Triton-X), 2.5 U Taq Polymerase (Promega,
Madison, WI, USA), 0.04 mM of each dNTP (CLON-
TECH, Palo Alto, CA, USA), and 5 ml of template
DNA.
The PCR reactions were performed in a PCR
thermocycler (Robocycler, Gradient 40, Strata-
gene, USA) at 30 repetitions of the cycle: 1 min
at 95 8C, 1 min at 55 8C, and 1 min 30 s at 72 8C. The
final cycle comprised 1 min at 95 8C, 1 min at 55 8C
and 5 min at 72 8C.
Nested PCR reactions
In cases where the ITS 3/4 amplification product
was weak and therefore not sufficient for restric-
tion endonuclease analysis, the template Malasse-
zia DNA from diseased skin scales was used for
amplification with the ITS 1/4 primers [13] under
the aforementioned PCR conditions. The product
was then subjected to nested PCR using the ITS
3/4 primers.
Sequencing of PCR products
The amplification products of the five Type
strains (M. sympodialis CBS 7222; M. slooffiae
CBS 7956; M. globosa CBS 7966; M. obtusa CBS
7876; M. restricta CBS 7877) and the two Neo-
type strains (M. furfur CBS 7019; M. pachydermatis
CBS 1879) were sequenced by Comfort Read1,
MWG-BIOTECH AG (Edersberg, Germany) and
a panel of restriction endonucleases was tested,
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so as to investigate whether the different spe-
cies would be differentiated from distinct RFLP
patterns.
Restriction fragment length polymorphism
(RFLP) analysis
The concentration of each ITS 3/4 amplification
product was estimated following brightness com-
parison with the MspI digest of the pBR322 DNA
molecular marker and 1mg was digested with 30 U
each of AluI, HinfI and MspI restriction endonu-
cleases (New England Biolabs, Beverly, MA, USA)
at a total volume of 30 ml in the supplied buffer,
and incubated at 37 8C for 2–16 h. Restriction frag-
ments were visualized under a UV transillumi-
nator (Herolab, E.A.S.Y., Weisloch, Germany) in
2.5–3% ethidium bromide-stained standard agar-
ose gels.
Reproducibility and stability of Malassezia
species populations
To test the stability and reproducibility of the
extraction method, and of the subsequent PCR-
RFLP results, a mean of five separate DNA extrac-
tions were performed from serial subcultures of
Malassezia Type, Neotype, Reference and clinical
isolates. In addition, DNA extractions and subse-
quent amplification reactions were carried out
from non-viable Malassezia cells from old cultures.
Multiple DNA extractions were also performed
from pure cultures of C. albicans strains (50 strains),
C. dubliniensis (20 strains), C. glabrata (50 strains), C.
parapsilosis (50 strains) and C. tropicalis (50 strains)
to test whether yeast species, residing on human
skin, can be distinguished from Malassezia species,
either by their amplicon size or by their character-
istic restriction patterns. In addition, a total of five
clinical Y. (Candida) lipolytica isolates were tested in
multiple trials, as it was noted that Y. lipolytica,
apart from being a causative agent for candidemia,
can be co-isolated in cultures of skin scales from
individuals with seborrheic dermatitis. Therefore,
it was considered necessary to determine whether
its ITS 3/4 amplification products could be differ-
entiated from those of Malassezia. DNA from pure
cultures of anamorphic basidiomycetous yeasts,
such as Filobasidiella (Cryptococcus) neoformans (50
strains), Trichosporon asahii (eight strains) and T.
mucoides (four strains), was also tested with the ITS
3/4 primers.
Relative sensitivity of PCR
The relative sensitivity of the method was deter-
mined, as previously described for Candida species
[12].
R E S U L T S
Malassezia species identification by PCR
The 5.8S rDNA and the ITS 2 region, amplified
from type, neotype, reference and clinical isolates
of Malassezia species by using the ITS 3 and 4
primers, differed in length among M. furfur, M.
sympodialis, M. globosa and M. pachydermatis
(Table 2). However, M. restricta could not always
be discriminated from M. slooffiae or M. pachyder-
matis in standard agarose gels, because, according
to sequencing data of the CBS Type and Neotype
strains the amplicons differ by only 76 and 73 bp,
respectively (Figures 1 and 2a); however, differen-
tiation among these species was attainable through
the HinfI and AluI restriction patterns, visualized
in 2.5% standard agarose gels (Figures 2a,b and 3).
Likewise, no difference in the 3/4 PCR products
was identified for M. furfur and M. obtusa, in
standard agarose gels, as they differed by only
3 bp (Figures 1 and 2a), but species identification
was feasible through the ITS 3/4 AluI restriction
pattern (Figure 3). No HinfI restriction site was
recognized on the M. furfur Reference strain
CBS 6001 (Figure 1). The noticeable migration
of the amplicon following incubation with Hinf I
Table 2 Malassezia Type, Neotype and clinical strains
RFLP of ITS 3/4 PCR products generated by AluI and HinfI
Malassezia
species
ITS 3/4
amplification
product (bp)
AluI digest
(bp)
Hinf I digest
(bp)
M. furfur 509 268, 241 483, 18, 8a
M. globosa 430 241, 173,
16a
412, 10, 8a
M. obtusa 506 NRS 480, 18, 8a
M. slooffiae 486 368, 118 403, 83b
M. restricta 410 NRS 392, 18, 8a
M. sympodialis 374 NRS 356, 10, 8a
M. pachy-
dermatis
483 374, 109 457, 18, 8a
NRS, no restriction site.
aRestriction fragment not visible in standard agarose gels.
bRestriction fragment occasionally visible in standard
agarose gels.
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Figure 1 Sequences of ITS 3/4 amplification products of Malassezia Type, Neotype and Reference CBS strains. HinfI restriction sites are marked in bold type and the
AluI sites are marked by arrows.
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(Figure 2, lane 1) is an occasionally misleading
artifact, often visible in standard agarose gels.
Amplified products from five Type and Neo-
type Malassezia strains, namely M. furfur CBS 7019,
M. obtusa CBS 7876, M. globosa CBS 7966, M.
pachydermatis CBS 1879 and M. restricta CBS 7877
had two HinfI recognition sites (Figure 1) produ-
cing different restriction patterns, which con-
firmed the identity of each species. Smaller
restriction fragments, of 100 bp or less, were not
perceptible in 2.5–3% standard agarose gels. How-
ever, digestion of amplicons could be visualized,
as judged by the relative migration of the resulting
larger restriction fragment in the gel (Figure 2a).
M. sympodialis CBS 7222 Type strain had only one
HinfI recognition site (Figure 1), but it produced a
clearly smaller product upon amplification using
either the ITS 3/4 (Figure 2a) or ITS 1/4 (data not
shown) primer pairs. Thus, it was readily differ-
entiated from all the other species by a single PCR.
M. obtusa, with no AluI restiction site, was dis-
criminated from M. furfur by its AluI ITS 3/4
distinct restriction pattern (Figure 3). None of
the clinical isolates tested produced atypical or
ambivalent AluI restriction patterns in comparison
with those presented in Figure 3 and all clinical M.
furfur HinfI restriction patterns conformed to that
of M. furfur CBS 7019 (Figure not shown). Also,
none of the Candida species tested produced HinfI
ITS 3/4 restriction patterns confusing the differ-
entiation of Malassezia species, as they were dis-
similar from those of Malassezia and distinct for
each Candida (figure not shown).
The ITS 3/4 amplification products of the other
basidiomycetous genera tested did not match
those of Malassezia species, as Filobasidiella (Cryp-
tococcus) neoformans, T. asahii and T. mucoides pro-
duced smaller amplicons of approximately 404
and 380 bp, respectively. They were also readily
differentiated from those of Malassezia by charac-
teristic AluI and HinfI restriction fragments (data
not shown).
Figure 2 ITS 3/4 amplification products and corresponding restriction fragments of Malassezia species from pure cultures
in 2.5–3% standard agarose gels. (a) Lane 1, M. furfur (Mf, CBS 6001); lane 3, M. globosa (Mg, GM 56); lane 6, M. obtusa (Mo,
CBS 7876); lane 8, M. restricta (Mr, CBS 7877); lane 10, M. sympodialis (Msy, CBS 7222); lane 13, M. pachydermatis (Mp, CBS
1879); lane 15, M. slooffiae (Ms, CBS 7956). Each Malassezia species tested is shown above the corresponding lanes. ITS 3/4
HinfI digests of each Malassezia species tested (panels a,b), lane 2, Mf (no restriction); lane 4, Mg; lane 7, Mo; lane 9, Mr; lane
11, Msy; lane 14, Mp; lane 17, Ms. Lanes 5, 12 and 16, molecular size marker MspI digest of pBR322 DNA.
Figure 3 ITS 3/4 AluI digests of Malassezia spp. Lane 1, M.
furfur (Mf) clinical strain; lane 2, M. obtusa (Mo) CBS 7876;
lane 3, M. slooffiae (Ms) CBS 7956; lane 4, M. pachydermatis
(Mp) (dog otitis); lane 5, M. restricta (Mr) (clinical strain);
lane 6, M. globosa (Mg) (clinical strain); lane 7, M. sympodialis
(Msy) CBS 7222. Lane 8, molecular size marker MspI digest
of pBR322 DNA. M. obtusa, M. restricta and M. sympodialis
do not possess a restriction site for AluI, while one site is
recognized on M. furfur, M. globosa, M. pachydermatis and
M. slooffiae differentiating all four of them.
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Reproducibility and stability of Malassezia
species populations
All the obtained Malassezia species-distinguishing
patterns from Type, Neotype, Reference and clin-
ical strains were reproducible upon testing DNA
from separate extractions and consequent restric-
tion digestions of the amplification products. As
expected, molecular identification of non-viable
Malassezia strains was in accordance with the
identification previously obtained by biochemical
and molecular methodology. Conventional spe-
cies classification and identification by the HinfI
and AluI ITS 3/4 digestions were found to be in
accordance in every independent assay.
Instability of certain Malassezia species in cul-
tures was observed on three occasions. Upon 10
consecutive subcultures of primary M. globosa and
M. restricta isolates, the former was outgrown, in
two cases by M. furfur and M. sympodialis, and the
latter by M. globosa. Despite this, the PCR-RFLP
method directly identified the concurrent presence
of mixed Malassezia species in a single specimen.
Sensitivity of the method
The relative sensitivity, as assayed using pure
cultures, was 10 5 CFU.
Susceptibility testing
The MIC ranges against Y. lipolytica were ampho-
tercin B, 0.25–0.5 mg/L; flucytosine, 1–16 mg/L;
fluconazole, from 8 to >64 mg/L; itraconazole,
0.5–3 mg/L; ketoconazole, 0.25–3 mg/L; and vor-
iconazole, 0.125–0.25 mg/L.
Malassezia species identification from
pathological skin scales
DNA extraction, amplification and endonuclease
digestion were successful in five of eleven patho-
logical specimens tested. The failure of DNA
extractions from the remaining six specimens
was attributed to the low yeast load of the skin
scales, as determined by microscopy, and subse-
quently, by the density of growth on Dixon’s
medium. Three of the five originated from pityr-
iasis versicolor and two from seborrheic dermatitis
cases. In the positive extractions from pathological
skin scales, the intensity of the ITS 3/4 amplifica-
tion product was proportional to the yeast load of
the skin scales. PCR-RFLP detected and identified
M. restricta and M. sympodialis from two patients
with seborrheic dermatitis and M. globosa from
three patients with pytiriasis versicolor. This
was later confirmed by positive culture and sub-
sequent biochemical tests.
In cases where inadequate amounts of PCR 3/4
products were obtained from skin-scale-extracted
DNA, nested PCR with ITS 3/4 following PCR
with the 1/4 primers was required in order to
augment the ITS 3/4 amplification products and
render them susceptible to restriction digestion. In
all cases, smearing was observed (Figure 4a,b)
upon electrophoresis of amplified target DNA
from skin scales. DNA purification procedures,
which would have improved the appearance of
the electrophoresed amplicon, were not underta-
ken, as this would have further diminished the
amount of extracted DNA.
On occasion, two or more PCR amplification
products were obtained using DNA extracted
from pathological skin scales. This was expected
as human skin usually accommodates more than
one Malassezia species. Again, whenever products
of the single PCR assay were weak, nested PCR
was required to obtain products sufficient for
endonuclease restriction.
As accounted for by the design of the study, a
second amplicon (approximately 330 bp) was
detected in one specimen of pathological material,
suggestive of the presence of a Candida species
(Figure 4a, lane 3). This amplicon size (approxi-
mately 330 bp) was indicative of C. albicans,
whereas that of 410 bp was indicative of M. restricta
(Figures 1 and 2a). Molecular identification was
consistent with the conventionally isolated and
identified M. restricta and C. albicans from the skin
scales of that patient. Subsequent digestion with
HinfI confirmed the presence of Malassezia and C.
albicans in the same specimen, as a mixed HinfI
restriction pattern was obtained (280 bp), corre-
sponding to C. albicans (data not shown) and
one representative of M. restricta (Figures 1 and
2a). A third amplification product of approxi-
mately 242 bp was also concurrently obtained with
that of M. restricta (Figure 4a). Again, cultures of
the pathological material and subsequent bio-
chemical tests confirmed the presence of Y. lipoly-
tica (Figure 4c). Y. lipolytica, producing an
amplicon of approximately 242 bp, no AluI restric-
tion site and two HinfI fragments (approximately
200 and 42 bp each), could be easily discriminated
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from Malassezia species by the amplification pro-
duct and by the RFLP pattern (Figure 4a,c).
D I S C U S S I O N
Alternative laboratory diagnosis, based on mole-
cular identification of each Malassezia species by
either specific probes [14] or PCR–restriction
enzyme analysis [15–17] has been employed using
pure cultures to assist and confirm conventional
laboratory diagnosis [5] of Malassezia-induced [18]
or -triggered [19] dermatological conditions.
Hitherto, there has not been, to our knowledge,
a method for identifying Malassezia species by
amplifying target DNA extracted directly from
skin scales, which could simultaneously reveal
potential interactions amongst Malassezia or other
yeast species on human skin.
The methodology illustrated here describes the
direct detection of Malassezia and species identifi-
cation after construction of a ‘library’ of HinfI and
AluI RFLPs derived from the ITS 3/4 amplicons of
each pure Malassezia species culture. The general
fungal oligonucleotide pair ITS 3/4 produced dis-
tinct amplicon sizes for two out of seven Malassezia
species, namely M. globosa and M. sympodialis, the
latter being readily distinguished by the smaller
amplification product as was also noted with the
ITS 1/4 primers [15].
Distinction of six out of seven Malassezia species,
M. furfur, M. globosa, M. restricta, M. sympodialis, M.
pachydermatis and M. slooffiae, was achievable upon
identifying polymorphisms following digestion of
the ITS 3/4 amplicon by HinfI and AluI. M. obtusa
was differentiated from M. furfur only by the AluI
3/4 distinct restriction pattern. The M. furfur CBS
7019 HinfI generated restriction pattern was com-
mon among all clinical M. furfur strains tested,
indicating prevalence of specific base sequences
among the wild-type M. furfur population. Simi-
larly, all HinfI and AluI restriction patterns of the
clinical isolates were consistent with those
obtained by sequencing the amplicons of Type
and Neotype strains.
Figure 4 ITS 3/4 direct Malassezia and other yeast species detection from seborrheic dermatitis (SD) and pityriasis
versicolor (PV) skin scales (Ssc) run in 2.5% standard agarose gels. (a) Lane 1, M. restricta from pure culture; lane 2, M.
restricta (Mr) amplicon incubated with AluI (no restriction site recognized); lane 3, amplified target DNA from SD
interscapular region skin scales identical to that of M. restricta (Ssc) incubated with AluI (no restriction site recognized).
This result was later confirmed by culture and conventional identification. The approximately 330 and 242 bp smaller
amplification products conform to those of C. albicans and Y. (Candida) lipolytica, respectively, the latter also isolated in
culture. No AluI sites are recognized on either of these secondary products. (b) Lane 6, amplified target DNA of
approximately 450 bp from trunk PV skin scales identical to that of M. globosa (Ssc); lane 7, AluI digest of the amplification
product identical to that obtained from Type and clinical pure cultures of M. globosa (SscAluI). Smearing, evident in lanes
3 and 6, was always obtained when target Ssc DNA was electrophoresed. (c) Y. lipolytica amplification products, HinfI and
AluI digests from pure cultures of interscapular region SD skin scales run in 3.5% MetaPhor agarose (FMC, Rockland, ME,
USA). Lanes 9 and 10, amplification products of Y. lipolytica (Yl) DNA from pure cultures; lane 11, HinfI digest (Y lHinfI).
The approximately 42 bp fragment was only visible in MetaPhore agarose. Lane 12, product incubated with AluI (YlAluI)
(no AluI restriction site recognized). Lanes 4, 5 and 8, molecular size marker MspI digest of pBR322 DNA.
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As the ITS 3/4 primers define, apart from the
ITS2 intervening region portions of the 5.8S and
18S genes, the HinfI restriction sites on control and
clinical strains alike, appear to be in the 5.8S
amplified sequences. The only exceptions
included the absence of a HinfI recognition site
on the M. furfur CBS 6001 ITS 3/4 amplicon and its
shift in the M. slooffiae amplification product.
The system proposed here allows the simulta-
neous detection and differentiation of different
Malassezia and Candida species in a single patho-
logical specimen. The implication of Candida spe-
cies and Yarrowia (Candida) lipolytica in a
Malassezia-induced dermatological condition,
may complicate the clinical picture, delay comple-
tion of laboratory tests and, in the case of Y.
lipolytica-associated seborrheic dermatitis, could
delay ketoconazole treatment when resistant
strains are implicated in the condition. This distant
relative of most ascomycete yeasts, which pro-
duces proteases and lipase and utilizes n-paraffins
[20,21], has also been isolated from pediatric sys-
temic infections and found to be refractory in vivo
and in vitro to the azoles [22]. Simultaneous iso-
lation of Y. lipolytica from fungal dermatitis of
captive gray seals, has been reported previously
[23] but the degree of interaction between the
lipase producer Y. lipolytica and the lipophilic
Malassezia species has not been studied in sebor-
rheic dermatitis, reported to recur despite applica-
tion of the recommended treatment, which also
includes topical ketoconazole [24,25].
Although no NCCLS break-points have been set
for Y. lipolytica, most of the tested isolates had
increased itraconazole and ketoconazole MIC.
The lowest MIC, for all strains, was recorded for
voriconazole, which, however, has not yet been
clinically evaluated against skin infections.
Trichophyton, Microsporum and Candida species
DNA from skin scales of patients has been success-
fully extracted previously [26]. However, in order
to obtain PCR products, 2 mg of pathological skin
scales were used, an unrealistically large amount
when collecting specimens from the majority of
Malassezia lesions. In the present study, the
sampled amount of skin scales from these lesions
was poor, and it can be particularly poor when
neonates in intensive care units are sampled using
a cotton swab. In such cases, the DNA-based
diagnostic methods are profoundly dependent
on the sensitivity of the nucleic acid extraction
procedure. However, it must be acknowledged
that, despite the sensitivity of the extraction
method, skin scales often contain a small amount
of the pathogen, contaminated by debris and
PCR-inhibiting components. Therefore, the final
DNA extract is frequently diminished due to
wasted nucleic acids during sample decontamina-
tion and extraction. In these instances, nested
PCR using the ITS 1/4 and ITS 3/4 primers can
be useful in the direct detection and identifica-
tion of Malassezia species. The benefit of using
general fungal primers was the co-detection
of non-Malassezia species in patient skin scales,
for which ITS PCR-RFLP patterns are already
known for many emerging opportunistic fungi
[11,12,27–30].
This non-culture diagnostic method applied on
dermatological specimens may be used routinely
to provide detection and identification of Malasse-
zia species. Admittedly, the current rate of success-
ful extractions of 45.5% from a single specimen
is low. It could be increased if more skin scales
were used from parasitized specimens, but this
was not always feasible, especially when sampling
small and scanty lesions. However, the relative
sensitivity of 10 5 yeast cells, as estimated using
pure cultures, matches that previously reported
for Candida species in spiked biological fluids
[11,12].
The proposed extraction method requires
further testing, using more skin-scale samples,
so that the observed simultaneous occurrence of
more than one species from a lesion [31] could be
directly detected and the results evaluated in a
larger patient population. Studying more samples
by using the maximum attainable skin-scale bio-
mass will define the precise limitations, absolute
sensitivity and reproducibility of this method.
These results indicate that the extraction method
can be applied to skin scales and demonstrate the
ability of the ITS3/4 PCR-RFLP method to directly
detect and identify Malassezia species, and their
shift, upon repeated DNA extractions and PCR-
RFLP experiments, from the same specimen. This
agreed with our observation on the replacement of
sensitive by more resistant Malassezia species, in
cultures of these specimens.
As pathogens or potential pathogens are not
always alone or prevalently implicated in skin
pathology, the ‘broad spectrum’ detection and
identification boundaries of the proposed method
may be of use in molecular taxonomy, epidemio-
logical studies and in the clinical laboratory.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 162–173
Gaitanis et al PCR identification of Malassezia species from skin scales 171
A C K N O W L E D G M E N T S
This study was partially supported by the State
Scholarship Foundation of Greece. We are grateful
to Gillian Midgley (London, UK), for donating
clinical isolates from her personal collection and
to Pfizer for providing voriconazole. The authors
express their appreciation to M. Logotheti and H.
Poutouri for their technical help and to Ariadne
and Philoktitis Abel for their contribution through
patience and understanding.
R E F E R E N C E S
1. Gue´ho E, Midgley G, Guillot J. The genus Malassezia
with description of four new species. Antonie Van
Leeuwenhoek 1996; 69: 337–55.
2. Midgley G, Gue´ho E, Guillot J. Diseases caused by
Malassezia species. In: Ajello J, Hay RJ, eds. Medical
Mycology, Topley and Wilson’s Microbiology and
Microbial Infections London, Sidney, Auckland:
Arnold, 1998: 201–11.
3. Van Belkum A, Boekhout T, Bosboom R. Monitor-
ing spread of Malassezia infections in a neonatal
intensive care unit by PCR-mediated genetic typ-
ing. J Clin Microbiol 1994; 32: 2528–32.
4. Archer-Dubon C, Icaza-Chivez ME, Orozco-Topette
R, Reyes E, Baez-Martinez R, de Ponce Leon S. An
epidemic outbreak of Malassezia folliculitis in three
adult patients in an intensive care unit: a previously
unrecognized nosocomial infection. Int J Dermatol
1999; 38: 453–6.
5. Guillot J, Gue´ho E, Lesourd M, Midgley G, Che´vrier
G, Dupont B. Identification of Malassezia species. A
practical approach. J Mycol Me´d 1996; 6: 103–10.
6. Mayser P, Haze P, Papavassilis C, Pickel M,
Gruender K, Gue´ho E. Differentiation of Malassezia
species: selectivity of Cremophor El, castor oil and
ricinoleic acid for M. furfur Br J Dermatol 1997; 137:
208–13.
7. Senczek D, Siesenop U, Bohm H. Characterization
of Malassezia species by means of phenotypic
characteristics and detection of electrophoretic
karyotypes by pulsed-field gel electrophoresis
(PFGE). Mycoses 1999; 42: 409–14.
8. Guillot J, Gue´ho E. The diversity of Malassezia yeasts
confirmed by rRNA sequence and nuclear DNA
comparisons. Antonie Van Leeuwenhoeck 1995; 67:
297–314.
9. Bond R, Anthony RM. Characterization of markedly
lipid-dependent Malassezia pachydermatis isolates
from healthy dogs. J Appl Bacteriol 1995; 78: 537–42.
10. National Committee for Clinical Laboratory Stan-
dards. Reference method for broth dilution antifungal
susceptibility testing of yeasts. Approved standard.
M27-A. Wayne, PA.: NCCLS, 1997.
11. Velegraki A, Kambouris M, Skiniotis G, Savala M,
Mitrousia A, Legakis NJ. Identification of medically
significant fungal genera by polymerase chain
reaction followed by restriction enzyme analysis.
FEMS Immun Med Microbiol 1999; 23: 303–12.
12. Velegraki A, Kambouris ME, Kostourou A, Chale-
velakis G, Legakis NJ. Rapid extraction of fungal
DNA from clinical samples for PCR amplification.
Med Mycol 1999; 37: 69–75.
13. White TJ, Bruns T, Lee S et al. Amplification and
direct sequencing of fungal ribosomal RNA genes
for phylogenetics. In: Innis MA, Gelfand DH,
Sninsky JJ, White TJ, eds. PCR protocols. A guide to
methods and applications. San Diego: Academic Press,
Inc., 1990; 315–22.
14. Anthony RM, Howell SA. Development of spe-
cies specific probes for Malassezia yeasts. In:
Negroni R, Arachevala A, , eds. Abstract’s Book XIV
Congress of the International Society for Human and
Animal Mycology (ISHAM) May 8–12, Buenos
Aires, Argentina. Buenos Aires: ISHAM, 2000;
Poster 178.
15. Gupta AK, Kohli Y, Summerbell RC. Molecular
differentiation of seven Malassezia species. J Clin
Microbiol 2000; 38: 1869–75.
16. Makimura K, Tamura Y, Kudo M, Uchida K, Saito
H, Yamaguchi H. Species identification and strain
typing of Malassezia species stock strains and
clinical isolates based on the DNA sequences of
nuclear ribosomal internal transcribed spacer 1
regions. J Med Microbiol 2000; 49: 29–35.
17. Guillot J, Deville M, Berthelemy M, Provost F,
Gue´ho E. A single PCR – restriction endonuclease
analysis for rapid identification of Malassezia
species. Lett Appl Microbiol 2000; 31: 400–3.
18. Gue´ho E, Boekhout T, Ashbee HR et al. The role of
Malassezia species in the ecology of human skin and
as pathogens. Med Mycol 1998; 36 (Suppl 1): 220–2.
19. Gue´ho E, Faergemann J, Lyman C, Anaissie EJ.
Malassezia and Trichosporon, two emerging patho-
genic basidiomycetous yeast-like fungi. J Med Vet
Mycol 1994; 32 (Suppl 1): 367–78.
20. Kurtzman CP, Robnett CJ. Orders and families of
ascosporogenous yeasts and yeast-like taxa com-
pared from ribosomal RNA sequence similarities.
In: Hawksworth DL, eds. Ascomycete systematics:
problems and perspectives in the nineties. New York:
Plenum Press, 1994; 249–58.
21. Kurtzman CP, Robnett CJ. Molecular relationships
among hyphal ascomycetous yeasts and yeastlike
taxa. Can J Bot 1995; 73: S824–S830.
22. Shin JH, Kook H, Shin DH et al. Nosocomial cluster
of Candida lipolytica fungemia in pediatric patients.
Eur J Clin Microbiol Infect Dis 2000; 19: 344–9.
23. Pollock CG, Rohrbach B, Ramsay EC. Fungal
dermatitis in captive pinnipeds. J Zoo Wildl Med
2000; 31: 374–8.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 162–173
172 Clinical Microbiology and Infection, Volume 8 Number 3, March 2002
24. Fitzpatric TB, Johnson RA, Wolff K et al. Color atlas
and synopsis of clinical dermatology. Common and serious
diseases, 3rd edn. New York, Tokyo, Toronto: Mc-
Graw-Hill, Health Professions Division, 1997; 72–5.
25. Johnson BA, Nunley JR. Treatment of seborrheic
dermatitis. Am Fam Physician 2000; 9: 2703–10.
26. Turin L, Riva F, Galbiati G, Cainelli T. Fast, simple
and highly sensitive double-rounded polymerase
chain reaction assay to detect medically relevant
fungi in dermatological specimens. Eur J Clin Invest
2000; 30: 511–8.
27. Williams DW, Wilson MJ, Lewis MAO, Potts AJC.
Identification of Candida species by PCR and
restriction fragment length polymorphism analysis
of intergenic spacer regions of ribosomal DNA. J
Clin Microbiol 1994; 32: 115–22.
28. Hazen KC. New and emerging yeast pathogens.
Clin Microbiol Rev 1995; 8: 462–78.
29. Perfect JR, Schell WA. The new fungal opportunists
are coming. Clin Infect Dis 22:s112–s18, 1996.
30. Coleman DC, Rinaldi MG, Haynes KA et al. Impor-
tance of Candida species other than Candida albicans
as opportunistic pathogens. Med Mycol 1998; 36
(Suppl 1): 156–65.
31. Gupta AK, Kohli Y, Summerbell RC et al. Quanti-
tative culture of Malassezia species form different
body sites with or without dermatoses. Med Mycol
1901; 39: 243–51.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 162–173
Gaitanis et al PCR identification of Malassezia species from skin scales 173
